Zymeworks Reports Strong Q4 Results Amid Positive Clinical Data and Revenue Growth

Zymeworks Inc. (ZWKS) reported a significant rebound in its fourth-quarter performance, posting revenue of $78.3 million, up 62% compared to the same period in the prior year. The growth was driven by increased product sales and milestone payments tied to collaborative agreements. The company also announced favorable top-line results from its Phase 2 trial of ZW25, a bispecific antibody targeting HER2-expressing solid tumors, with a confirmed objective response rate of 41% in patients with advanced gastric cancer. The strong financials and clinical progress were pivotal in exceeding analyst expectations. Adjusted EBITDA improved to a positive $12.1 million, a reversal from the prior-year loss, reflecting better cost control and revenue scaling. Zymeworks extended its cash runway to over 24 months, bolstering its ability to advance multiple late-stage programs without near-term capital raises. The market reacted swiftly, with ZWKS shares rising 18% in after-hours trading. The move contributed to a broader rally in the healthcare sector, with the iShares Biotechnology ETF (IBB) gaining 3.2% and the Vanguard Health Care ETF (VHT) up 1.9%. Investors are increasingly favoring biotech firms with validated clinical data and diversified pipelines. Zymeworks is advancing several candidates, including ZW25 and ZW49, with potential regulatory submissions expected in 2027. The company has also expanded its manufacturing capacity in preparation for commercial launch scenarios. Market analysts now project ZWKS could generate over $200 million in annual revenue by 2029 if current trial outcomes hold.